(CDAX, Automobile & Parts)



| Dung | Value Indicators: | CHF | Share data: | | Description: | |
|------------------|--------------------------|--------|---------------------|--------------|----------------------------|---------|
| Buy | DCF: | 79.37 | Bloomberg: | PMAG GR | Europe's largest manufacti | uror of |
| our 70 00 | FCF-Value Potential 21e: | 80.23 | Reuters: | PMAG.VI | sports motorcycles. | ulei oi |
| CHF 79.00 | | | ISIN: | AT0000KTMI02 | , | |
| | Market Snapshot: | CHF m | Shareholders: | | Risk Profile (WRe): | 2020e |
| Drice OUE 52 | Market cap: | 1,215 | Freefloat | 38.0 % | Beta: | 1.4 |
| Price CHF 53. | No. of snares (m): | 23 | Pierer Industrie AG | 62.0 % | Price / Book: | 3.1 x |
| Upside 46.6 | % EV: | 1,892 | Remaining managemen | nt 1.1 % | Equity Ratio: | 39 % |
| | Freefloat MC: | 462 | | | Net Fin. Debt / EBITDA: | 1.9 x |
| | Ø Trad. Vol. (30d): | 1.14 m | | | Net Debt / EBITDA: | 2.0 x |

Preliminaries in line with our forecasts

Pierer Mobility yesterday (22.07.2020) published preliminary sales and EBIT figures for H1 2020. With a two-month production interruption, the company generated sales of ca. EUR 600m vs. EUR 754.9m in H1 19, a decline of 20.5% yoy. EBIT reached EUR 1.7m vs. EUR 46.6m in H1 19. In the light of the dramatic operating measures that had to be made, we regard the performance as impressive

There was surprisingly strong development in the motorcycle customer end-market, particularly in North America (+20%). Globally, motorcycle registrations rose by around 4% in H1 2020 despite COVID-19 lockdowns. According to Pierer Mobility, KTM and Husqvarna achieved wholesale market share gains, especially in the US market.

As we were expecting, the company gave a sales guidance for the full year 2020 of approximately EUR 1,400m (WRe: EUR 1,439.8m). The ebike segment should contribute around EUR 110m, which is in line with our estimate, and 57.1% growth yoy. In H2 2020, group sales growth of 4.5% yoy is assumed by Pierer Mobility. Against the backdrop of empty dealer warehouses, we regard the H2 sales guidance as cautious. The company is producing at full capacity again and there should be some catch-up effects on wholesale revenues during H2 2020. To this end, 170 new employees were hired for the Austrian production facility after production resumed in early June.

We continue to expect FY EBIT of EUR 69m. We regard the preliminary figures as very robust especially considering that production had to be stopped for two months. The company should give a profitability and FCF guidance with publication of final H1 figures on August 31. In our view, this will be the next trigger event.

While COVID-19 will interrupt the group's growth story in 2020e, it could also offer opportunities in the form of further consolidation within the industry. Latest market data is encouraging that Pierer will be able to partially catch up on lost revenue, as customers are putting greater focus on individual mobility. Furthermore, we expect Pierer to continue to gain market share, as its operational and supply chain performance is strong even in a tough market environment. Pierer can capitalise on a strong balance sheet (equity ratio >38%) and a solid liquidity situation (WRe: ~200m). We think the company could even benefit and steer the consolidation among European motorcycle manufacturers or at least take advantage of its strong B2B dealer network.

Our estimates and PT remain unchanged as the preliminary figures totally confirmed our forecasts. We stick to our recommendation. Buy.




| Rel. Performance vs CDAX: | |
|---------------------------|---------|
| 1 month: | 8.8 % |
| 6 months: | 11.1 % |
| Year to date: | 3.2 % |
| Trailing 12 months: | -11.8 % |
| | |

| Company events: | |
|-----------------|----|
| 31.08.20 | H1 |
| | |

| FY End: 31.12. in EUR m | CAGR (19-22e) | 2016 | 2017 | 2018 | 2019 | 2020e | 2021e | 2022e |
|----------------------------|------------------|--------|--------|--------|--------|--------|--------|--------|
| Sales | 6.2 % | 1,343 | 1,354 | 1,462 | 1,520 | 1,440 | 1,642 | 1,819 |
| Change Sales yoy | | 9.8 % | 0.8 % | 8.0 % | 4.0 % | -5.3 % | 14.0 % | 10.8 % |
| Gross profit margin | | 32.3 % | 30.2 % | 29.6 % | 29.3 % | 27.0 % | 29.0 % | 29.0 % |
| EBITDA | 7.4 % | 198 | 194 | 211 | 241 | 200 | 270 | 298 |
| Margin | | 14.8 % | 14.3 % | 14.4 % | 15.8 % | 13.9 % | 16.5 % | 16.4 % |
| EBIT | 2.0 % | 122 | 122 | 129 | 132 | 69 | 126 | 140 |
| Margin | | 9.1 % | 9.0 % | 8.8 % | 8.7 % | 4.8 % | 7.7 % | 7.7 % |
| Net income | -1.3 % | 52 | 45 | 67 | 54 | 22 | 46 | 52 |
| EPS | -1.3 % | 2.30 | 1.98 | 2.99 | 2.42 | 0.98 | 2.06 | 2.33 |
| EPS adj. | -1.3 % | 2.30 | 1.77 | 1.82 | 2.42 | 0.98 | 2.06 | 2.33 |
| DPS | - | 0.03 | 0.30 | 0.30 | 0.00 | 0.30 | 0.30 | 0.30 |
| Dividend Yield | | 0.1 % | 0.6 % | 0.5 % | n.a. | 0.6 % | 0.6 % | 0.6 % |
| FCFPS | | 1.05 | -0.77 | -4.35 | 4.10 | 1.35 | 2.90 | 3.13 |
| EV / Sales | | 1.3 x | 1.6 x | 1.6 x | 1.4 x | 1.2 x | 1.2 x | 1.1 x |
| EV / EBITDA | | 9.0 x | 11.0 x | 11.0 x | 9.0 x | 8.8 x | 7.3 x | 6.6 x |
| EV / EBIT | | 14.6 x | 17.5 x | 18.1 x | 16.4 x | 25.5 x | 15.6 x | 14.1 x |
| P/E | | 15.7 x | 26.0 x | 20.8 x | 21.3 x | 51.1 x | 24.3 x | 21.5 x |
| P / E adj. | | 15.7 x | 29.1 x | 34.1 x | 21.3 x | 51.1 x | 24.3 x | 21.5 x |
| FCF Potential Yield | | 6.2 % | 4.7 % | 6.2 % | 6.7 % | 6.5 % | 8.1 % | 8.9 % |
| Net Debt | | 388 | 399 | 348 | 425 | 397 | 349 | 295 |
| ROE | | 22.0 % | 15.1 % | 21.9 % | 17.1 % | 6.3 % | 12.2 % | 12.4 % |
| ROCE (NOPAT) | | 12.2 % | 10.0 % | 10.7 % | 11.0 % | 4.9 % | 8.9 % | 9.7 % |
| Guidance: | Guidance with | ıdrawn | | | | | | |






Company Background

- PMAG, is the biggest European motorcycle manufacturer and a global leader in off-road motorcycles. The company operates under the brands KTM, Husqvarna Motorcycles & GASGAS which are marketed separately.
- Racing plays an important role in generating new sales and winning new customers in both segments. In motorcycle racing, the driver is the hero and the brand is associated with the face of the winning driver.
- According to PMAG, wins can be translated 1-to-1 into off-road sales, while this effect is less pronounced for street motorcycles.
- Besides motorcycles, PMAG has set ambitious sales targets for its eBike business (Husqvarna E-Bikes) of more than 80K units and roughly EUR 110m sales for 2020e already, while only targeting Europe in a first step.

Competitive Quality

- PMAG is the market leader in Europe and has a strong footprint in USA (market share 12% and 9% respectively). Despite that, off-road is PMAG's legacy business where it benefits from a 70% market share in Europe.
- Customers look for quality and brands, which PMAG can offer as its products offer technically differentiated product features. A substantial amount of time and capital is needed to achieve the technology level of PMAG.
- Even stricter emission regulation disadvantages smaller players and new entrants and serve as a barrier to entry. At the same time it generates chances for M&A.
- PMAG is the industry leader in R&D spending, which enables it to defend its existing product offering and quickly understand new trends.
- PMAG created a unique vertical supply chain which ensures production of all critical and performance related components in house (WP, engines).





| DCF model | | | | | | | | | | | | | | |
|-----------------------------|---------|-----------|----------|--------|--------|--------|--------|-----------|-----------|--------|--------|--------|--------|-------------|
| | Detaile | d forecas | t period | | | | ٦ | ransition | al period | | | | | Term. Value |
| Figures in EUR m | 2020e | 2021e | 2022e | 2023e | 2024e | 2025e | 2026e | 2027e | 2028e | 2029e | 2030e | 2031e | 2032e | |
| Sales | 1,440 | 1,642 | 1,819 | 2,001 | 2,171 | 2,328 | 2,472 | 2,602 | 2,718 | 2,822 | 2,913 | 2,993 | 3,064 | |
| Sales change | -5.3 % | 14.0 % | 10.8 % | 10.0 % | 8.5 % | 7.2 % | 6.2 % | 5.3 % | 4.5 % | 3.8 % | 3.2 % | 2.8 % | 2.3 % | 2.0 % |
| EBIT | 69 | 125 | 138 | 170 | 183 | 196 | 206 | 216 | 224 | 231 | 237 | 242 | 247 | |
| EBIT-margin | 4.8 % | 7.6 % | 7.6 % | 8.5 % | 8.4 % | 8.4 % | 8.3 % | 8.3 % | 8.2 % | 8.2 % | 8.1 % | 8.1 % | 8.0 % | |
| Tax rate (EBT) | 25.0 % | 25.0 % | 25.0 % | 25.0 % | 25.5 % | 25.9 % | 26.4 % | 26.9 % | 27.4 % | 27.9 % | 28.4 % | 28.9 % | 29.5 % | |
| NOPAT | 51 | 94 | 104 | 128 | 137 | 145 | 152 | 158 | 163 | 167 | 170 | 172 | 174 | |
| Depreciation | 131 | 145 | 160 | 130 | 137 | 144 | 149 | 152 | 155 | 157 | 158 | 158 | 157 | |
| in % of Sales | 9.1 % | 8.9 % | 8.8 % | 6.5 % | 6.3 % | 6.2 % | 6.0 % | 5.9 % | 5.7 % | 5.6 % | 5.4 % | 5.3 % | 5.1 % | |
| Changes in provisions | -2 | 2 | 0 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | |
| Change in Liquidity from | | | | | | | | | | | | | | |
| - Working Capital | -9 | 4 | 22 | 8 | 24 | 22 | 19 | 17 | 15 | 13 | 11 | 9 | 8 | |
| - Capex | 145 | 155 | 155 | 160 | 166 | 171 | 174 | 175 | 175 | 174 | 172 | 170 | 166 | |
| Capex in % of Sales | 10.1 % | 9.4 % | 8.5 % | 8.0 % | 7.7 % | 7.3 % | 7.0 % | 6.7 % | 6.4 % | 6.2 % | 5.9 % | 5.7 % | 5.4 % | |
| Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Free Cash Flow (WACC Model) | 44 | 82 | 87 | 92 | 87 | 98 | 110 | 120 | 129 | 138 | 146 | 152 | 158 | 163 |
| PV of FCF | 42 | 73 | 73 | 72 | 63 | 67 | 70 | 72 | 72 | 72 | 71 | 69 | 67 | 1,403 |
| share of PVs | | 8.20 % | | | | | | 30.45 | 5 % | | | | | 61.35 % |

| Model parameter | | | | Valuation (m) | | | |
|--------------------------|---------|---------------------|------|----------------------------|-------|-----------------------|-------|
| Derivation of WACC: | | Derivation of Beta: | | Present values 2032e | 884 | | |
| | | | | Terminal Value | 1,403 | | |
| Debt ratio | 30.00 % | Financial Strength | 1.30 | Financial liabilities | 609 | | |
| Cost of debt (after tax) | 1.7 % | Liquidity (share) | 1.50 | Pension liabilities | 27 | | |
| Market return | 7.00 % | Cyclicality | 1.50 | Hybrid capital | 0 | | |
| Risk free rate | 1.50 % | Transparency | 1.40 | Minority interest | 232 | | |
| | | Others | 1.30 | Market val. of investments | 14 | | |
| | | | | Liquidity | 239 | No. of shares (m) | 22.5 |
| WACC | 6.97 % | Beta | 1.40 | Equity Value | 1,672 | Value per share (EUR) | 74.17 |

| Sens | itivity Va | lue per Sh | are (EUR |) | | | | | | | | | | | | | |
|------|------------|------------|----------|--------|--------|--------|--------|--------|------|-------|-----------|---------|---------|---------|---------|---------|---------|
| | | Terminal (| Growth | | | | | | | | Delta EBI | -margin | | | | | |
| Beta | WACC | 1.25 % | 1.50 % | 1.75 % | 2.00 % | 2.25 % | 2.50 % | 2.75 % | Beta | WACC | -1.5 pp | -1.0 pp | -0.5 pp | +0.0 pp | +0.5 pp | +1.0 pp | +1.5 pp |
| 1.66 | 8.0 % | 50.44 | 52.02 | 53.73 | 55.58 | 57.60 | 59.80 | 62.21 | 1.66 | 8.0 % | 37.46 | 43.50 | 49.54 | 55.58 | 61.63 | 67.67 | 73.71 |
| 1.53 | 7.5 % | 57.58 | 59.54 | 61.68 | 64.01 | 66.57 | 69.38 | 72.49 | 1.53 | 7.5 % | 44.16 | 50.78 | 57.39 | 64.01 | 70.63 | 77.25 | 83.86 |
| 1.46 | 7.2 % | 61.61 | 63.81 | 66.21 | 68.84 | 71.74 | 74.94 | 78.51 | 1.46 | 7.2 % | 48.00 | 54.95 | 61.90 | 68.84 | 75.79 | 82.74 | 89.68 |
| 1.40 | 7.0 % | 66.01 | 68.48 | 71.19 | 74.17 | 77.47 | 81.14 | 85.25 | 1.40 | 7.0 % | 52.25 | 59.55 | 66.86 | 74.17 | 81.48 | 88.79 | 96.10 |
| 1.34 | 6.7 % | 70.81 | 73.61 | 76.68 | 80.08 | 83.86 | 88.09 | 92.85 | 1.34 | 6.7 % | 56.95 | 64.66 | 72.37 | 80.08 | 87.79 | 95.50 | 103.21 |
| 1.27 | 6.5 % | 76.10 | 79.26 | 82.76 | 86.66 | 91.01 | 95.92 | 101.48 | 1.27 | 6.5 % | 62.19 | 70.34 | 78.50 | 86.66 | 94.81 | 102.97 | 111.13 |
| 1.14 | 6.0 % | 88.38 | 92.51 | 97.14 | 102.34 | 108.25 | 115.01 | 122.82 | 1.14 | 6.0 % | 74.69 | 83.91 | 93.12 | 102.34 | 111.56 | 120.78 | 130.00 |

- Sales growth slows from 10% to 2% in perpetuity.
- EBIT margin declines during transitional phase from 8.5% to 8%.
- EBIT used in our DCF differs from EBIT in the P&L as we exclude at-equity earnings...
- ... and separately add at-equity participations at book value. We deduct minority interest at 14x minority earnings.



Free Cash Flow Value Potential

Warburg Research's valuation tool "FCF Value Potential" reflects the ability of the company to generate sustainable free cash flows. It is based on the "FCF potential" - a FCF "ex growth" figure - which assumes unchanged working capital and pure maintenance capex. A value indication is derived via the perpetuity of a given year's "FCF potential" with consideration of the weighted costs of capital. The fluctuating value indications over time add a timing element to the DCF model (our preferred valuation tool).

| in EUR m | | 2016 | 2017 | 2018 | 2019 | 2020e | 2021e | 2022e |
|--|--------|--------|--------|--------|--------|--------|--------|--------|
| Net Income before minorities | | 89 | 84 | 114 | 96 | 39 | 81 | 92 |
| + Depreciation + Amortisation | | 76 | 72 | 82 | 109 | 131 | 144 | 159 |
| - Net Interest Income | | -13 | -13 | -16 | -14 | -18 | -17 | -17 |
| - Maintenance Capex | | 67 | 68 | 73 | 76 | 72 | 82 | 91 |
| + Other | | 0 | 0 | 4 | 1 | 0 | -1 | -1 |
| = Free Cash Flow Potential | | 111 | 101 | 144 | 144 | 114 | 160 | 176 |
| FCF Potential Yield (on market EV) |) | 6.2 % | 4.7 % | 6.2 % | 6.7 % | 6.5 % | 8.1 % | 8.9 % |
| WACC | | 6.97 % | 6.97 % | 6.97 % | 6.97 % | 6.97 % | 6.97 % | 6.97 % |
| = Enterprise Value (EV) | | 1,781 | 2,137 | 2,324 | 2,162 | 1,757 | 1,967 | 1,977 |
| = Fair Enterprise Value | | 1,591 | 1,448 | 2,061 | 2,066 | 1,641 | 2,298 | 2,522 |
| - Net Debt (Cash) | | 396 | 396 | 396 | 396 | 370 | 320 | 266 |
| - Pension Liabilities | | 29 | 29 | 29 | 29 | 27 | 29 | 29 |
| - Other | | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Market value of minorities | | 577 | 577 | 577 | 577 | 232 | 490 | 554 |
| + Market value of investments | | 14 | 14 | 14 | 14 | 14 | 16 | 17 |
| = Fair Market Capitalisation | | 603 | 459 | 1,072 | 1,077 | 1,027 | 1,474 | 1,690 |
| Number of shares, average | | 23 | 23 | 23 | 23 | 23 | 23 | 23 |
| = Fair value per share (EUR) | | 26.74 | 20.37 | 47.58 | 47.78 | 45.55 | 65.41 | 74.98 |
| premium (-) / discount (+) in % | | | | | | -9.0 % | 30.7 % | 49.8 % |
| Sensitivity Fair value per Share (I | EUR) | | | | | | | |
| | 9.97 % | 5.49 | 1.04 | 20.05 | 20.19 | 23.62 | 34.72 | 41.30 |
| | 8.97 % | 10.99 | 6.04 | 27.18 | 27.34 | 29.30 | 42.67 | 50.02 |
| | 7.97 % | 17.88 | 12.31 | 36.10 | 36.28 | 36.40 | 52.61 | 60.93 |
| WACC | 6.97 % | 26.74 | 20.37 | 47.58 | 47.78 | 45.55 | 65.41 | 74.98 |
| | 5.97 % | 38.58 | 31.14 | 62.91 | 63.15 | 57.75 | 82.51 | 93.74 |
| | 4.97 % | 55.18 | 46.25 | 84.41 | 84.70 | 74.88 | 106.48 | 120.05 |
| | 3.97 % | 80.16 | 68.97 | 116.76 | 117.12 | 100.64 | 142.55 | 159.63 |

[•] We expect maintenance Capex at 5% of sales.

^{• &}quot;Others" include the adjustments from at-equity earnings which we separately add at book value.

Additionally, we deduct minority interest at 14x minority earnings.



| Valuation | | | | | | | |
|--|------------|--------|--------|--------|--------|--------|--------|
| | 2016 | 2017 | 2018 | 2019 | 2020e | 2021e | 2022e |
| Price / Book | 3.0 x | 3.7 x | 4.7 x | 3.4 x | 3.1 x | 2.8 x | 2.5 x |
| Book value per share ex intangibles | -3.89 | -3.49 | -5.56 | -8.16 | -8.27 | -7.19 | -5.42 |
| EV / Sales | 1.3 x | 1.6 x | 1.6 x | 1.4 x | 1.2 x | 1.2 x | 1.1 x |
| EV / EBITDA | 9.0 x | 11.0 x | 11.0 x | 9.0 x | 8.8 x | 7.3 x | 6.6 x |
| EV / EBIT | 14.6 x | 17.5 x | 18.1 x | 16.4 x | 25.5 x | 15.6 x | 14.1 x |
| EV / EBIT adj.* | 14.6 x | 17.5 x | 17.4 x | 16.2 x | 25.6 x | 15.8 x | 14.3 x |
| P/FCF | 34.5 x | n.a. | n.a. | 12.5 x | 36.9 x | 17.2 x | 16.0 x |
| P/E | 15.7 x | 26.0 x | 20.8 x | 21.3 x | 51.1 x | 24.3 x | 21.5 x |
| P / E adj.* | 15.7 x | 29.1 x | 34.1 x | 21.3 x | 51.1 x | 24.3 x | 21.5 x |
| Dividend Yield | 0.1 % | 0.6 % | 0.5 % | n.a. | 0.6 % | 0.6 % | 0.6 % |
| FCF Potential Yield (on market EV) | 6.2 % | 4.7 % | 6.2 % | 6.7 % | 6.5 % | 8.1 % | 8.9 % |
| *Adjustments made for: One-offs and Pankl deconsolidat | ion effect | | | | | | |


| Company Specific Items | | | | | | | |
|------------------------|---------|---------|---------|---------|---------|---------|---------|
| | 2016 | 2017 | 2018 | 2019 | 2020e | 2021e | 2022e |
| Total KTM Bikes | 172,636 | 201,451 | 212,898 | 234,449 | 200,252 | 222,317 | 236,046 |
| Total Husqvarna Bikes | 30,787 | 36,883 | 48,554 | 45,650 | 41,002 | 71,283 | 103,400 |
| Total GASGAS Bikes | 0 | 0 | 0 | 0 | 4,500 | 13,000 | 16,000 |
| Sales share off-road | 50.0 % | 45.0 % | 40.0 % | 39.0 % | 36.0 % | 34.0 % | 34.0 % |
| Sales share on-road | 50.0 % | 55.0 % | 60.0 % | 61.0 % | 64.0 % | 66.0 % | 66.0 % |
| eBikes sold | 0 | 0 | 30,000 | 60,000 | 83,000 | 103,000 | 120,000 |



| Consolidated profit and loss | | | | | | | |
|---|----------|--------|--------|--------|--------|--------|--------|
| In EUR m | 2016 | 2017 | 2018 | 2019 | 2020e | 2021e | 20226 |
| Sales | 1,343 | 1,354 | 1,462 | 1,520 | 1,440 | 1,642 | 1,819 |
| Change Sales yoy | 9.8 % | 0.8 % | 8.0 % | 4.0 % | -5.3 % | 14.0 % | 10.8 % |
| COGS | 909 | 945 | 1,029 | 1,074 | 1,051 | 1,166 | 1,291 |
| Gross profit | 434 | 409 | 433 | 446 | 389 | 476 | 527 |
| Gross margin | 32.3 % | 30.2 % | 29.6 % | 29.3 % | 27.0 % | 29.0 % | 29.0 % |
| Research and development | 40 | 34 | 27 | 24 | 29 | 41 | 45 |
| Sales and marketing | 170 | 165 | 172 | 215 | 194 | 230 | 255 |
| Administration expenses | 80 | 60 | 71 | 84 | 85 | 90 | 100 |
| Other operating expenses | 28 | 32 | 30 | 1 | 19 | 2 | 2 |
| Other operating income | 5 | 4 | 0 | 11 | 7 | 11 | 13 |
| Unfrequent items | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | 198 | 194 | 211 | 241 | 200 | 270 | 298 |
| Margin | 14.8 % | 14.3 % | 14.4 % | 15.8 % | 13.9 % | 16.5 % | 16.4 % |
| Depreciation of fixed assets | 43 | 38 | 43 | 53 | 60 | 64 | 70 |
| EBITA | 156 | 156 | 168 | 188 | 139 | 206 | 229 |
| Amortisation of intangible assets | 33 | 34 | 39 | 56 | 70 | 80 | 89 |
| Goodwill amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | 122 | 122 | 129 | 132 | 69 | 126 | 140 |
| Margin | 9.1 % | 9.0 % | 8.8 % | 8.7 % | 4.8 % | 7.7 % | 7.7 % |
| EBIT adj. | 122 | 122 | 134 | 133 | 69 | 125 | 138 |
| Interest income | 3 | 2 | 3 | 3 | 3 | 3 | 3 |
| Interest expenses | 20 | 13 | 18 | 17 | 19 | 18 | 18 |
| Other financial income (loss) | 3 | -2 | -1 | 0 | -2 | -2 | -2 |
| EBT | 109 | 109 | 112 | 118 | 51 | 109 | 123 |
| Margin | 8.1 % | 8.1 % | 7.7 % | 7.8 % | 3.6 % | 6.6 % | 6.7 % |
| Total taxes | 20 | 30 | 27 | 22 | 13 | 27 | 31 |
| Net income from continuing operations | 89 | 79 | 85 | 96 | 39 | 81 | 92 |
| Income from discontinued operations (net of tax) | 0 | 5 | 5 | 0 | 0 | 0 | 0 |
| Net income before minorities | 89 | 84 | 114 | 96 | 39 | 81 | 92 |
| Minority interest | 37 | 39 | 47 | 41 | 17 | 35 | 40 |
| Net income | 52 | 45 | 67 | 54 | 22 | 46 | 52 |
| Margin | 3.9 % | 3.3 % | 4.6 % | 3.6 % | 1.5 % | 2.8 % | 2.9 % |
| Number of shares, average | 23 | 23 | 23 | 23 | 23 | 23 | 23 |
| EPS | 2.30 | 1.98 | 2.99 | 2.42 | 0.98 | 2.06 | 2.33 |
| EPS adj. | 2.30 | 1.77 | 1.82 | 2.42 | 0.98 | 2.06 | 2.33 |
| *Adjustments made for: One-offs and Pankl deconsolidation | n offoct | | | | | | |

Guidance: Guidance withdrawn

| Financial Ratios | | | | | | | |
|-------------------------------|---------|---------|---------|---------|---------|---------|---------|
| | 2016 | 2017 | 2018 | 2019 | 2020e | 2021e | 2022e |
| Total Operating Costs / Sales | 23.2 % | 21.2 % | 20.5 % | 20.6 % | 22.2 % | 21.4 % | 21.4 % |
| Operating Leverage | 0.9 x | -0.4 x | 0.7 x | 0.6 x | 9.0 x | 5.9 x | 1.0 x |
| EBITDA / Interest expenses | 10.2 x | 15.3 x | 11.4 x | 14.2 x | 10.8 x | 14.7 x | 16.5 x |
| Tax rate (EBT) | 18.5 % | 27.6 % | 24.2 % | 18.8 % | 25.0 % | 25.0 % | 25.0 % |
| Dividend Payout Ratio | 0.8 % | 8.6 % | 7.9 % | 0.0 % | 17.5 % | 8.3 % | 7.3 % |
| Sales per Employee | 264,936 | 322,856 | 339,817 | 348,016 | 348,016 | 348,016 | 348,016 |




and Source, Warburg Research Source, Warburg Research



| Consolidated balance sheet | | | | | | | |
|---|-------|-------|-------|-------|-------|-------|-------|
| In EUR m | 2016 | 2017 | 2018 | 2019 | 2020e | 2021e | 2022 |
| Assets | | | | | | | |
| Goodwill and other intangible assets | 362 | 397 | 423 | 522 | 547 | 562 | 56 |
| thereof other intangible assets | 244 | 280 | 327 | 392 | 416 | 432 | 438 |
| thereof Goodwill | 118 | 117 | 96 | 130 | 130 | 130 | 130 |
| Property, plant and equipment | 303 | 357 | 283 | 326 | 316 | 312 | 302 |
| Financial assets | 6 | 15 | 26 | 14 | 14 | 16 | 17 |
| Other long-term assets | 11 | 6 | 9 | 15 | 15 | 17 | 19 |
| Fixed assets | 682 | 775 | 742 | 878 | 892 | 906 | 900 |
| Inventories | 252 | 297 | 287 | 322 | 313 | 328 | 357 |
| Accounts receivable | 122 | 120 | 149 | 175 | 174 | 184 | 204 |
| Liquid assets | 284 | 169 | 89 | 161 | 239 | 281 | 32 |
| Other short-term assets | 84 | 104 | 87 | 78 | 74 | 85 | 94 |
| Current assets | 741 | 691 | 612 | 736 | 800 | 878 | 98′ |
| Total Assets | 1,424 | 1,465 | 1,354 | 1,614 | 1,692 | 1,785 | 1,888 |
| Liabilities and shareholders' equity | | | | | | | |
| Subscribed capital | 225 | 225 | 23 | 23 | 23 | 23 | 2: |
| Capital reserve | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Retained earnings | 0 | 0 | 0 | 0 | 0 | 0 | (|
| Other equity components | 39 | 83 | 265 | 306 | 328 | 367 | 413 |
| Shareholders' equity | 274 | 318 | 297 | 338 | 360 | 400 | 446 |
| Minority interest | 181 | 211 | 253 | 280 | 293 | 319 | 349 |
| Total equity | 455 | 529 | 551 | 619 | 653 | 719 | 79 |
| Provisions | 41 | 50 | 43 | 49 | 47 | 49 | 49 |
| thereof provisions for pensions and similar obligations | 24 | 24 | 25 | 29 | 27 | 29 | 29 |
| Financial liabilities (total) | 648 | 544 | 413 | 557 | 609 | 601 | 59 |
| thereof short-term financial liabilities | 191 | 171 | 73 | 86 | 86 | 86 | 8 |
| Accounts payable | 131 | 178 | 191 | 223 | 221 | 243 | 26 |
| Other liabilities | 149 | 164 | 157 | 167 | 163 | 173 | 18 |
| Liabilities | 969 | 937 | 803 | 995 | 1,039 | 1,066 | 1,093 |
| Total liabilities and shareholders' equity | 1,424 | 1,465 | 1,354 | 1,614 | 1,692 | 1,785 | 1,888 |


| Financial Ratios | | | | | | | |
|-------------------------------------|---------|---------|---------|---------|---------|---------|--------|
| | 2016 | 2017 | 2018 | 2019 | 2020e | 2021e | 2022e |
| Efficiency of Capital Employment | | | | | | | |
| Operating Assets Turnover | 2.5 x | 2.3 x | 2.8 x | 2.5 x | 2.5 x | 2.8 x | 3.1 x |
| Capital Employed Turnover | 1.6 x | 1.5 x | 1.6 x | 1.5 x | 1.4 x | 1.5 x | 1.7 x |
| ROA | 7.6 % | 5.8 % | 9.1 % | 6.2 % | 2.5 % | 5.1 % | 5.8 % |
| Return on Capital | | | | | | | |
| ROCE (NOPAT) | 12.2 % | 10.0 % | 10.7 % | 11.0 % | 4.9 % | 8.9 % | 9.7 % |
| ROE | 22.0 % | 15.1 % | 21.9 % | 17.1 % | 6.3 % | 12.2 % | 12.4 % |
| Adj. ROE | 22.0 % | 13.5 % | 13.4 % | 17.1 % | 6.3 % | 12.2 % | 12.4 % |
| Balance sheet quality | | | | | | | |
| Net Debt | 388 | 399 | 348 | 425 | 397 | 349 | 295 |
| Net Financial Debt | 365 | 375 | 323 | 396 | 370 | 320 | 266 |
| Net Gearing | 85.3 % | 75.5 % | 63.2 % | 68.7 % | 60.7 % | 48.5 % | 37.1 % |
| Net Fin. Debt / EBITDA | 183.7 % | 193.3 % | 153.2 % | 164.4 % | 185.2 % | 118.4 % | 89.1 % |
| Book Value / Share | 12.2 | 14.1 | 13.2 | 15.0 | 16.0 | 17.7 | 19.8 |
| Book value per share ex intangibles | -3.9 | -3.5 | -5.6 | -8.2 | -8.3 | -7.2 | -5.4 |





| Consolidated cash flow statement | | | | | | | |
|--|------|------|------|------|-------|-------|-------|
| In EUR m | 2016 | 2017 | 2018 | 2019 | 2020e | 2021e | 2022e |
| Net income | 89 | 84 | 114 | 96 | 39 | 81 | 92 |
| Depreciation of fixed assets | 43 | 38 | 43 | 53 | 60 | 64 | 70 |
| Amortisation of goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Amortisation of intangible assets | 33 | 34 | 39 | 56 | 70 | 80 | 89 |
| Increase/decrease in long-term provisions | 3 | 0 | 1 | 4 | -2 | 2 | 0 |
| Other non-cash income and expenses | -4 | 28 | -29 | -23 | 0 | -3 | -3 |
| Cash Flow before NWC change | 164 | 185 | 168 | 186 | 167 | 225 | 247 |
| Increase / decrease in inventory | 13 | -36 | -58 | 58 | 9 | -15 | -28 |
| Increase / decrease in accounts receivable | -25 | -44 | -26 | 13 | 2 | -11 | -20 |
| Increase / decrease in accounts payable | 16 | 56 | 1 | 0 | -2 | 22 | 26 |
| Increase / decrease in other working capital positions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Increase / decrease in working capital (total) | 4 | -23 | -83 | 71 | 9 | -4 | -22 |
| Net cash provided by operating activities [1] | 168 | 161 | 85 | 257 | 176 | 220 | 226 |
| Investments in intangible assets | -69 | -74 | -93 | -110 | -95 | -95 | -95 |
| Investments in property, plant and equipment | -75 | -105 | -90 | -55 | -50 | -60 | -60 |
| Payments for acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Financial investments | 0 | 9 | 16 | -1 | 0 | 0 | 0 |
| Income from asset disposals | 7 | 27 | 70 | 0 | 0 | 0 | 0 |
| Net cash provided by investing activities [2] | -159 | -154 | -102 | -166 | -145 | -155 | -155 |
| Change in financial liabilities | 206 | -97 | -39 | 5 | 52 | -8 | -8 |
| Dividends paid | -18 | -20 | -19 | -20 | 0 | -7 | -7 |
| Purchase of own shares | 0 | 0 | 0 | -5 | 0 | 0 | 0 |
| Capital measures | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other | -49 | 0 | -6 | 0 | -4 | -9 | -10 |
| Net cash provided by financing activities [3] | 139 | -118 | -63 | -21 | 48 | -24 | -25 |
| Change in liquid funds [1]+[2]+[3] | 148 | -111 | -80 | 71 | 78 | 42 | 46 |
| Effects of exchange-rate changes on cash | 0 | -4 | 0 | 0 | 0 | 0 | 0 |
| Cash and cash equivalent at end of period | 283 | 169 | 89 | 161 | 239 | 281 | 327 |

| Financial Ratios | | | | | | | |
|--------------------------------------|---------|---------|----------|---------|---------|---------|---------|
| | 2016 | 2017 | 2018 | 2019 | 2020e | 2021e | 2022e |
| Cash Flow | | | | | | | |
| FCF | 24 | -17 | -98 | 92 | 31 | 65 | 71 |
| Free Cash Flow / Sales | 1.8 % | -1.3 % | -6.7 % | 6.1 % | 2.1 % | 4.0 % | 3.9 % |
| Free Cash Flow Potential | 111 | 101 | 144 | 144 | 114 | 160 | 176 |
| Free Cash Flow / Sales | 1.8 % | -1.3 % | -6.7 % | 6.1 % | 2.1 % | 4.0 % | 3.9 % |
| Free Cash Flow / Net Profit | 45.6 % | -38.7 % | -145.4 % | 169.7 % | 138.8 % | 141.0 % | 134.4 % |
| Interest Received / Avg. Cash | 1.3 % | 1.0 % | 2.7 % | 2.4 % | 1.5 % | 1.2 % | 1.0 % |
| Interest Paid / Avg. Debt | 3.3 % | 2.1 % | 3.9 % | 3.5 % | 3.2 % | 3.0 % | 3.0 % |
| Management of Funds | | | | | | | |
| Investment ratio | 10.7 % | 13.2 % | 12.6 % | 10.8 % | 10.1 % | 9.4 % | 8.5 % |
| Maint. Capex / Sales | 5.0 % | 5.0 % | 5.0 % | 5.0 % | 5.0 % | 5.0 % | 5.0 % |
| Capex / Dep | 189.4 % | 248.0 % | 223.0 % | 151.2 % | 111.1 % | 107.5 % | 97.7 % |
| Avg. Working Capital / Sales | 18.1 % | 17.8 % | 16.6 % | 17.1 % | 18.7 % | 16.3 % | 15.4 % |
| Trade Debtors / Trade Creditors | 93.1 % | 67.4 % | 78.4 % | 78.7 % | 78.6 % | 75.9 % | 75.9 % |
| Inventory Turnover | 3.6 x | 3.2 x | 3.6 x | 3.3 x | 3.4 x | 3.5 x | 3.6 x |
| Receivables collection period (days) | 33 | 32 | 37 | 42 | 44 | 41 | 41 |
| Payables payment period (days) | 53 | 69 | 68 | 76 | 77 | 76 | 76 |
| Cash conversion cycle (Days) | 82 | 78 | 71 | 76 | 76 | 68 | 66 |



Source: Warburg Research Source: Warburg Research Source: Warburg Research



LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.



Additional information for clients in the United States

- 1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
- 2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
- 3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
- 4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
- 5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation
- -3- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or**investment services and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

| Company | Disclosure | Link to the historical price targets and rating changes (last 12 months) |
|--------------------|------------|--|
| PIERER Mobility AG | 5 | http://www.mmwarburg.com/disclaimer/disclaimer en/AT0000KTMI02.htm |

10



INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

| -B- | Buy: | The price of the analysed financial instrument is expected to rise over the next 12 months. |
|------------|-------------------|---|
| -H- | Hold: | The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months. |
| -S- | Sell: | The price of the analysed financial instrument is expected to fall over the next 12 months. |
| "_" | Rating suspended: | The available information currently does not permit an evaluation of the company. |

| Rating | Number of stocks | % of Universe |
|------------------|------------------|---------------|
| Buy | 127 | 62 |
| Hold | 59 | 29 |
| Sell | 12 | 6 |
| Rating suspended | 7 | 3 |
| Total | 205 | 100 |

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

| Rating | Number of stocks | % of Universe |
|------------------|------------------|---------------|
| Buy | 32 | 80 |
| Hold | 6 | 15 |
| Sell | 0 | 0 |
| Rating suspended | 2 | 5 |
| Total | 40 | 100 |

PRICE AND RATING HISTORY PIERER MOBILITY AG AS OF 23.07.2020



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



| EQUITIES | | | |
|---|---|--|--|
| Matthias Rode | +49 40 3282-2678 | | |
| Head of Equities | mrode@mmwarburg.com | | |
| RESEARCH | | | |
| Michael Heider Head of Research | +49 40 309537-280 | Thilo Kleibauer Retail, Consumer Goods | +49 40 309537-257 |
| Henner Rüschmeier | mheider@warburg-research.com +49 40 309537-270 | Eggert Kuls | tkleibauer@warburg-research.com +49 40 309537-256 |
| Head of Research | hrueschmeier@warburg-research.com | Engineering | ekuls@warburg-research.com |
| Stefan Augustin Cap. Goods, Engineering | +49 40 309537-168 saugustin@warburg-research.com | Andreas Pläsier Banks, Financial Services | +49 40 309537-246 aplaesier@warburg-research.com |
| Jan Bauer Renewables | +49 40 309537-155 jbauer@warburg-research.com | Malte Schaumann Technology | +49 40 309537-170 mschaumann@warburg-research.com |
| Jonas Blum Telco, Construction | +49 40 309537-240 jblum@warburg-research.com | Patrick Schmidt Leisure, Internet | +49 40 309537-125 pschmidt@warburg-research.com |
| Christian Cohrs | +49 40 309537-175 | Oliver Schwarz | +49 40 309537-250 |
| Industrials & Transportation Felix Ellmann | ccohrs@warburg-research.com +49 40 309537-120 | Chemicals, Agriculture Simon Stippig | oschwarz@warburg-research.com +49 40 309537-265 |
| Software, IT | fellmann@warburg-research.com | Real Estate | sstippig@warburg-research.com |
| Jörg Philipp Frey Retail, Consumer Goods | +49 40 309537-258 jfrey@warburg-research.com | Cansu Tatar Cap. Goods, Engineering | +49 40 309537-248 ctatar@warburg-research.com |
| Marius Fuhrberg Financial Services | +49 40 309537-185 mfuhrberg@warburg-research.com | Marc-René Tonn Automobiles, Car Suppliers | +49 40 309537-259 mtonn@warburg-research.com |
| Mustafa Hidir | +49 40 309537-230 | Robert-Jan van der Horst | +49 40 309537-290 |
| Automobiles, Car Suppliers | mhidir@warburg-research.com | Technology Andreas Wolf | rvanderhorst@warburg-research.com |
| Ulrich Huwald Health Care, Pharma | +49 40 309537-255 uhuwald@warburg-research.com | Software, IT | +49 40 309537-140 awolf@warburg-research.com |
| Philipp Kaiser Real Estate | +49 40 309537-260 | | |
| INSTITUTIONAL EQU | pkaiser@warburg-research.com | | |
| Marc Niemann | +49 40 3282-2660 | Tobias Hald | +49 40 3282-2695 |
| Head of Equity Sales, Germany | mniemann@mmwarburg.com | United Kingdom | thald@mmwarburg.com |
| Klaus Schilling | +49 40 3282-2664 | Maximilian Martin | +49 69 5050-7413 |
| Head of Equity Sales, Germany Tim Beckmann | kschilling@mmwarburg.com +49 40 3282-2665 | Austria, Poland Christopher Seedorf | mmartin@mmwarburg.com +49 69 5050-7414 |
| United Kingdom | tbeckmann@mmwarburg.com | Switzerland | cseedorf@mmwarburg.com |
| Lyubka Bogdanova Ireland, Poland, Australia | +49 69 5050-7411 lbogdanova@mmwarburg.com | | |
| Jens Buchmüller | +49 69 5050-7415 | | |
| Scandinavia, Austria | jbuchmueller@mmwarburg.com | | |
| Alexander Eschweiler Germany, Luxembourg | +49 40 3282-2669 aeschweiler@mmwarburg.com | Sophie Hauer Roadshow/Marketing | +49 69 5050-7417 shauer@mmwarburg.com |
| Matthias Fritsch | +49 40 3282-2696 | Juliane Niemann | +49 40 3282-2694 |
| United Kingdom | mfritsch@mmwarburg.com | Roadshow/Marketing | jniemann@mmwarburg.com |
| SALES TRADING | | | |
| Oliver Merckel Head of Sales Trading | +49 40 3282-2634 | Marcel Magiera Sales Trading | +49 40 3282-2662 |
| Elyaz Dust | omerckel@mmwarburg.com +49 40 3282-2702 | Bastian Quast | mmagiera@mmwarburg.com +49 40 3282-2701 |
| Sales Trading | edust@mmwarburg.com | Sales Trading | bquast@mmwarburg.com |
| Michael Ilgenstein Sales Trading | +49 40 3282-2700 milgenstein@mmwarburg.com | Jörg Treptow Sales Trading | +49 40 3282-2658 jtreptow@mmwarburg.com |
| MACRO RESEARCH | go.is.co.i.ga.za.igice.ii | - Calco Francis | j. opton@a.aa.ig.co |
| Carsten Klude | +49 40 3282-2572 | Dr. Christian Jasperneite | +49 40 3282-2439 |
| Macro Research | cklude@mmwarburg.com | Investment Strategy | cjasperneite@mmwarburg.com |
| Our research can be | | | |
| Warburg Research | research.mmwarburg.com/en/index.html | Thomson Reuters | www.thomsonreuters.com |
| Bloomberg FactSet | MMWA GO www.factset.com | Capital IQ | www.capitaliq.com |
| For access please conta | act: | | |
| Andrea Schaper | +49 40 3282-2632 | Kerstin Muthig | +49 40 3282-2703 |
| Sales Assistance | aschaper@mmwarburg.com | Sales Assistance | kmuthig@mmwarburg.com |